Cormedix Q2 revenue, EBITDA rise; guidance lifted
Cormedix reported second-quarter revenue of $101.9 million and adjusted EBITDA of $58.7 million, signed a multi-year DefenCath supply deal with another large dialysis organization, and raised full-year adjusted EBITDA guidance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.